Avilés A, Talavera A, Guzmán R, Cuadra I
Department of Hematology, Oncology Hospital, National Medical Center, Mexico, D.F., Mexico.
Cancer Biother. 1995 Winter;10(4):273-7. doi: 10.1089/cbr.1995.10.273.
We report the results of a clinical trial of chlorambucil (CB) alternating with interferon alfa 2b (IFN) in previously treated patients with low-grade lymphoma who were refractory to previous treatment. Patients received CB 10 mg/m2, po, daily, days 1-14, alternating with IFN 5.0 MU three times a week days 15-28 (six doses) by six monthly cycles. If partial response was achieved, patients received extended field radiotherapy to sites of nodal residual postchemotherapy disease. Forty-three patients were enrolled into the study, and 30 were evaluable for response and toxicity. Nineteen out of 39 (40%) achieved complete remission and 14 out of 39 (35%) had partial remission, thus the overall response was observed in 83% of the cases. Ten patients with partial response and residual nodal disease received radiotherapy and achieved complete response criteria. The median duration of response has not been achieved, yet, 23 patients remain in complete response after a median follow-up of 98.5 months. Toxicity was mild and 95% of the patients received the planned dose of CB and IFN. These results suggest that combination of CB and IFN and addition of radiotherapy to residual postchemotherapy nodal disease may be effective in patients with low-grade lymphoma without excessive toxicity and adequate quality of life.
我们报告了一项针对先前接受过治疗且对先前治疗无效的低度淋巴瘤患者进行的苯丁酸氮芥（CB）与干扰素α2b（IFN）交替治疗的临床试验结果。患者在第1 - 14天口服CB 10 mg/m²，每日一次，在第15 - 28天（六剂）每周三次交替使用IFN 5.0 MU，共六个周期，为期六个月。如果达到部分缓解，患者将接受扩大野放射治疗，针对化疗后残留淋巴结疾病部位。43名患者入组该研究，30名患者可评估疗效和毒性。39名患者中有19名（40%）达到完全缓解，39名中有14名（35%）达到部分缓解，因此83%的病例观察到总体缓解。10名部分缓解且有残留淋巴结疾病的患者接受放射治疗并达到完全缓解标准。目前尚未达到中位缓解持续时间，然而，在中位随访98.5个月后，23名患者仍处于完全缓解状态。毒性轻微，95%的患者接受了计划剂量的CB和IFN。这些结果表明，CB与IFN联合使用以及对化疗后残留淋巴结疾病进行放射治疗，对于低度淋巴瘤患者可能有效，且无过度毒性，生活质量良好。
